表紙
市場調査レポート

1型糖尿病 (若年性糖尿病) :パイプライン製品の分析

Type 1 diabetes (Juvenile Diabetes) - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 232787
出版日 ページ情報 英文 631 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.75円で換算しております。
Back to Top
1型糖尿病 (若年性糖尿病) :パイプライン製品の分析 Type 1 diabetes (Juvenile Diabetes) - Pipeline Review, H1 2016
出版日: 2016年06月08日 ページ情報: 英文 631 Pages
概要

1型糖尿病 (若年性糖尿病) とは、膵臓がインスリンの生産を中断するという自己免疫疾患です。人体の免疫系が膵臓内部のインスリン生産細胞 (β細胞) を攻撃・破壊することで発症します。主な疾病素質として、先天性疾患や家族歴、膵臓疾患、感染症などが挙げられています。主な徴候・症状には、深刻な渇きや頻繁な尿意、極度の空腹感、体重減少、倦怠感、いらつき、非日常的行動などが挙げられます。治療に際しては、生活習慣の改善や提起的な薬物療法が必要となります。

当レポートでは、世界における1型糖尿病 (若年性糖尿病) 治療薬のパイプライン製品の開発状況について分析しており、製品開発・上市の最新動向や治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

型糖尿病 (若年性糖尿病) の概要

治療薬の開発

型糖尿病 (若年性糖尿病):企業で開発中の治療薬

型糖尿病 (若年性糖尿病):大学/機関で研究中の治療薬

型糖尿病 (若年性糖尿病):パイプライン製品の概況

型糖尿病 (若年性糖尿病):企業で開発中の製品

型糖尿病 (若年性糖尿病):大学/機関で研究中の製品

型糖尿病 (若年性糖尿病)の治療薬開発に従事している企業

型糖尿病 (若年性糖尿病):治療薬の評価

薬剤プロファイル

型糖尿病 (若年性糖尿病):最近のパイプライン動向

型糖尿病 (若年性糖尿病):休止中のプロジェクト

型糖尿病 (若年性糖尿病):開発が中止された製品

型糖尿病 (若年性糖尿病):製品開発のマイルストーン

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7967IDB

Summary

Global Markets Direct's, 'Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H1 2016', provides an overview of the Type 1 Diabetes (Juvenile Diabetes) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Type 1 Diabetes (Juvenile Diabetes), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Type 1 Diabetes (Juvenile Diabetes) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Type 1 Diabetes (Juvenile Diabetes)
  • The report reviews pipeline therapeutics for Type 1 Diabetes (Juvenile Diabetes) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Type 1 Diabetes (Juvenile Diabetes) therapeutics and enlists all their major and minor projects
  • The report assesses Type 1 Diabetes (Juvenile Diabetes) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Type 1 Diabetes (Juvenile Diabetes)

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Type 1 Diabetes (Juvenile Diabetes)
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Type 1 Diabetes (Juvenile Diabetes) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
  • Type 1 diabetes (Juvenile Diabetes) Overview
  • Therapeutics Development
  • Type 1 diabetes (Juvenile Diabetes) - Therapeutics under Development by Companies
  • Type 1 diabetes (Juvenile Diabetes) - Therapeutics under Investigation by Universities/Institutes
  • Type 1 diabetes (Juvenile Diabetes) - Pipeline Products Glance
  • Type 1 diabetes (Juvenile Diabetes) - Products under Development by Companies
  • Type 1 diabetes (Juvenile Diabetes) - Products under Investigation by Universities/Institutes
  • Type 1 diabetes (Juvenile Diabetes) - Companies Involved in Therapeutics Development
  • Type 1 diabetes (Juvenile Diabetes) - Therapeutics Assessment
  • Drug Profiles
  • Type 1 diabetes (Juvenile Diabetes) - Recent Pipeline Updates
  • Type 1 diabetes (Juvenile Diabetes) - Dormant Projects
  • Type 1 diabetes (Juvenile Diabetes) - Discontinued Products
  • Type 1 diabetes (Juvenile Diabetes) - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Type 1 diabetes (Juvenile Diabetes), H1 2016
  • Number of Products under Development for Type 1 diabetes (Juvenile Diabetes) - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Development by Companies, H1 2016 (Contd..1)
  • Number of Products under Development by Companies, H1 2016 (Contd..2)
  • Number of Products under Development by Companies, H1 2016 (Contd..3)
  • Number of Products under Development by Companies, H1 2016 (Contd..4)
  • Number of Products under Development by Companies, H1 2016 (Contd..5)
  • Number of Products under Development by Companies, H1 2016 (Contd..6)
  • Number of Products under Development by Companies, H1 2016 (Contd..7)
  • Number of Products under Development by Companies, H1 2016 (Contd..8)
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..1)
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Comparative Analysis by Unknown Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Development by Companies, H1 2016 (Contd..2)
  • Products under Development by Companies, H1 2016 (Contd..3)
  • Products under Development by Companies, H1 2016 (Contd..4)
  • Products under Development by Companies, H1 2016 (Contd..5)
  • Products under Development by Companies, H1 2016 (Contd..6)
  • Products under Development by Companies, H1 2016 (Contd..7)
  • Products under Development by Companies, H1 2016 (Contd..8)
  • Products under Development by Companies, H1 2016 (Contd..9)
  • Products under Development by Companies, H1 2016 (Contd..10)
  • Products under Development by Companies, H1 2016 (Contd..11)
  • Products under Development by Companies, H1 2016 (Contd..12)
  • Products under Investigation by Universities/Institutes, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016 (Contd..1)
  • Type 1 diabetes (Juvenile Diabetes) - Pipeline by AbGenomics International, Inc., H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Pipeline by Adocia, H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Pipeline by AiCuris GmbH & Co. KG, H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Pipeline by Alteogen Inc., H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Pipeline by Amarantus Bioscience Holdings, Inc., H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Pipeline by Ambrx, Inc., H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Pipeline by AntriaBio, Inc., H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Pipeline by Aphios Corporation, H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Pipeline by APT Therapeutics, Inc., H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Pipeline by Araim Pharmaceuticals, Inc., H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Pipeline by Argos Therapeutics, Inc., H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Pipeline by Artery Therapeutics, Inc., H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Pipeline by Astellas Pharma Inc., H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Pipeline by AstraZeneca Plc, H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Pipeline by Athersys, Inc., H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Pipeline by Axxam SpA, H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Pipeline by Beta-Cell NV, H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Pipeline by Biocon Limited, H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Pipeline by Biodel Inc., H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Pipeline by Biogenomics Limited, H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Pipeline by BioLineRx, Ltd., H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Pipeline by BioLingus AG, H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Pipeline by BioTherapeutics Inc., H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Pipeline by Boehringer Ingelheim GmbH, H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Pipeline by Caladrius Biosciences, Inc. , H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Pipeline by Carlina Technologies SAS, H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Pipeline by Cellectis S.A., H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Pipeline by Compugen Ltd., H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Pipeline by Daewoong Pharmaceutical Co., Ltd., H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Pipeline by Dance Biopharm Inc., H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Pipeline by Diabetology (Products) Ltd, H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Pipeline by DiaMedica Inc., H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Pipeline by Diamyd Medical AB, H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Pipeline by Diasome Pharmaceuticals, Inc., H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Pipeline by Dompe Farmaceutici S.p.A., H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Pipeline by Effimune S.A., H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Pipeline by Eli Lilly and Company, H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Pipeline by enGene, Inc, H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Pipeline by Ensol Biosciences Inc., H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Pipeline by EpiVax, Inc., H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Pipeline by Evotec AG, H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Pipeline by Fate Therapeutics, Inc., H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Pipeline by Generex Biotechnology Corporation, H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Pipeline by GeNeuro SA, H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Pipeline by Geropharm, H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Pipeline by Gilead Sciences, Inc., H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Pipeline by GlaxoSmithKline Plc, H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Pipeline by Grifols, S.A., H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Pipeline by Heptares Therapeutics Limited, H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Pipeline by Iltoo Pharma, H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Pipeline by Innopharmax Inc., H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Pipeline by IntelliCell BioSciences Inc., H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Pipeline by Intrexon Corporation, H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Pipeline by Islet Sciences, Inc., H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Pipeline by Johnson & Johnson, H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Pipeline by Kadimastem Ltd., H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Pipeline by Kamada Ltd., H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Pipeline by Kasiak Research Private Limited, H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Pipeline by Kineta, Inc., H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Pipeline by Kissei Pharmaceutical Co., Ltd., H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Pipeline by Lexicon Pharmaceuticals, Inc., H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Pipeline by Ligand Pharmaceuticals, Inc., H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Pipeline by Lonestar Heart, Inc., H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Pipeline by MacroGenics, Inc., H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Pipeline by Medestea Research & Production S.p.A., H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Pipeline by MedImmune, LLC, H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Pipeline by Merck & Co., Inc., H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Pipeline by Meridigen Biotech Co., Ltd., H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Pipeline by MidaSol Therapeutics LP, H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Pipeline by NOD Pharmaceuticals, Inc., H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Pipeline by Novo Nordisk A/S, H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Pipeline by Noxxon Pharma AG, H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Pipeline by Oramed Pharmaceuticals, Inc., H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Pipeline by Orgenesis, Inc., H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Pipeline by Paras Biopharmaceuticals Finland Oy, H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Pipeline by Parvus Therapeutics, Inc., H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Pipeline by Pathfinder Cell Therapy, Inc., H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Pipeline by Pfizer Inc., H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Pipeline by PharmaCyte Biotech, Inc., H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Pipeline by PharmaIN Corporation, H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Pipeline by Progen Pharmaceuticals Limited, H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Pipeline by Prometheon Pharma, LLC, H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Pipeline by Purzer Pharmaceutical Co., Ltd., H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Pipeline by RedHill Biopharma Ltd., H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Pipeline by REGiMMUNE Corporation, H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Pipeline by Sanofi, H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Pipeline by SEKRIS Biomedical, Inc., H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Pipeline by Selecta Biosciences, Inc., H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Pipeline by Sevion Therapeutics, Inc., H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Pipeline by Strongbridge Biopharma plc , H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Pipeline by Therapix Biosciences Ltd, H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Pipeline by Thermalin Diabetes, LLC, H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Pipeline by Toleranzia AB, H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Pipeline by Transgene Biotek Limited, H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Pipeline by UCB S.A., H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Pipeline by Uni-Bio Science Group Ltd., H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Pipeline by United Therapeutics Corporation, H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Pipeline by ViaCyte, Inc., H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Pipeline by Visionary Pharmaceuticals, Inc., H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Pipeline by XL-protein GmbH, H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Pipeline by XOMA Corporation, H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Pipeline by Zensun (Shanghai) Sci & Tech Co., Ltd., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Type 1 diabetes (Juvenile Diabetes) Therapeutics - Recent Pipeline Updates, H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Dormant Projects, H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Dormant Projects (Contd..1), H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Dormant Projects (Contd..2), H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Dormant Projects (Contd..3), H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Dormant Projects (Contd..4), H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Dormant Projects (Contd..5), H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Dormant Projects (Contd..6), H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Dormant Projects (Contd..7), H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Dormant Projects (Contd..8), H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Dormant Projects (Contd..9), H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Dormant Projects (Contd..10), H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Dormant Projects (Contd..11), H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Discontinued Products, H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Discontinued Products (Contd..1), H1 2016
  • Type 1 diabetes (Juvenile Diabetes) - Discontinued Products (Contd..2), H1 2016

List of Figures

  • Number of Products under Development for Type 1 diabetes (Juvenile Diabetes), H1 2016
  • Number of Products under Development for Type 1 diabetes (Juvenile Diabetes) - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Top 10 Routes of Administration, H1 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2016
  • Number of Products by Top 10 Molecule Types, H1 2016
  • Number of Products by Stage and Top 10 Molecule Types, H1 2016
Back to Top